Abstract
Monkeypox virus (MPXV) resides in two forms, mature and enveloped virions, and depending on it, distinct proteins are displayed on the viral surface. We expressed in mammalian cells two MPXV antigens from the mature form and two MPXV antigens from the enveloped form and tested their reactivity to sera of 11 MPXV convalescent donors diagnosed in Israel during May-June 2022 and collected 33-62 days post infection. While only 4 out of 11 donors neutralized the related Vaccinia Lister strain, all MPXV recoverees demonstrated a strong serological response to a 124-amino acid truncation of the A35R antigen, and to a 276-amino acid truncation of the H3L antigen. Moreover, A35R- and H3L-specific B cells ranging from 0.03-0.5% and 0.01-0.35% of IgG+CD19+ cells, respectively, were detected in all 11 MPXV donors (A35R), and in 8 out of 11 donors (H3L). Therefore, A35R and H3L represent MPXV immune targets, and can be used in a simple heat-inactivated serological enzyme-linked immunosorbent assay for the identification of recent MPXV infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by Tel Aviv University
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Statement: All MPXV convalescent donors between the ages of 23 and 39 provided a written informed consent prior to participating in this study. All donors tested positive in a PCR assay for MPXV infection collected from saliva, blood, anus, or blisters. A single sample of 170 mL of whole blood was collected 33-62 days post infection, 2-3 weeks after the donors were considered recovered. Tel Aviv University Institutional Review Board approved all studies involving patient enrollment, sample collection, and clinical follow-up. Tel Aviv University Institutional Review Board ethics approval has been granted (protocol number 0005243-1). Donors were followed by the Dermatology Division of Ichilov Tel Aviv Sourasky Medical Center (Helsinki approval number 0384-22-TLV). The uninfected >50 and uninfected <40 samples were collected from the Israeli Blood bank, Tel Aviv University Institutional Review Board approval protocol number 0004554-2. Ethics approval has been granted.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
There has been a mistake in the order of the authors in the HTML. Additionally the middle initial of one of the authors was missing. The order of the authors is now correct. Look forward to see the revised version. All the best wishes, Natalia
Data Availability
All data produced in the present study are available upon reasonable request to the authors
